News Headlines

  1. Sanofi To Acquire Synthorx To Bolster Its Immuno-Oncology Pipeline For $2.5B 12/9/2019

    Sanofi and Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Synthorx for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion (on a fully diluted basis).

  2. Autoimmune Technologies Announces New Subsidiary To Develop Novel Antibody And Allogeneic Somatic Stem Cell Therapeutics For The Treatment Of Invasive Candidiasis And Other Infectious Disease 12/9/2019

    Autoimmune Technologies LLC, a biotechnology company developing diagnostics and therapies for non-infectious and infectious disease, has established a new subsidiary, Stadius Biopharma LLC, to focus on proprietary anti-infective antibody therapeutics for diseases that are inadequately addressed by current standard-of-care medicines.

  3. Thermo Fisher Scientific Opens $90 Million Viral Vector Manufacturing Site in Massachusetts 12/5/2019

    New facility will create 200 new jobs and accelerate commercialization of gene and cell therapies.

  4. Fujifilm Establishes The Bio Science & Engineering Laboratories U.S.A. To Start Full-Scale Translational Research For Biotherapeutics In The United States 12/5/2019

    FUJIFILM Corporation (President: Kenji Sukeno) announced that it has begun full-scale research activities to advance the field of translational research for biotherapeutics at its newly established “Bio Science & Engineering Laboratories U.S.A.”

  5. VGXI Selects BE&K As Design Firm For New 240,000 Square Foot Manufacturing Facility 12/3/2019

    VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has chosen the integrated construction services company BE&K Building Group as Design-Build Partner for the initial phase of its new manufacturing site.

  6. Boehringer Ingelheim Chooses NiceLabel Solution To Help Support Standardized Labeling Worldwide 12/2/2019

    Global pharmaceutical company, Boehringer Ingelheim, has selected NiceLabel, a leading global developer of label design software and label management systems, to help it create a global standardized labeling process.

  7. Speeding Cell, Gene Therapy Development 11/25/2019

    An innovative new major private-public partnership led by Harvard and MIT aims to accelerate one of the hottest and most promising areas of medical research: cell and gene therapy

  8. Heraeus Expands Cancer Therapy API Capacity 11/22/2019

    Heraeus Pharmaceutical Ingredients, a business line of Heraeus Precious Metals, has expanded its capacity for Platinum-based highly potent active pharmaceutical ingredients (Pt HPAPIs) with an additional production line built at the company’s headquarters in Hanau, Germany.

  9. WuXi Vaccines To Build A $240M Manufacturing Facility In Ireland 11/22/2019

    WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, engaged in human vaccine Contract Development and Manufacturing Organization (CDMO) business, is to invest 240 million USD and build a new vaccine manufacturing facility in Ireland.

  10. AstraZeneca Partnership Gives Significant Boost To Sun Pharma’s Overall China Entry Strategy, Says GlobalData 11/21/2019

    Sun Pharmaceutical Industries Ltd (Sun Pharma) has recently entered into a licensing agreement with AstraZeneca UK to launch novel ready-to-use oncology drugs in China.